Overview

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

Status:
RECRUITING
Trial end date:
2026-03-15
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
Phase:
PHASE2
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.